Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Hockings H, Lakatos E, Huang W, Mossner M, Khan MA, Bakali N, McDermott J, Smith K et al.
Cancer Research, American Association For Cancer Research (Aacr) 
29-04-2025

Abstract SY43-01: Translating adaptive therapy to ovarian cancer patients
Khan MA, Hockings H, Mossner M, Baker A-M, Amy H, Hollis RL, Huang W, Lakatos E et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 85 (8_Supplement_2) 
25-04-2025

A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population☆
Merry E, Kesmez RT, Yu T, Flynn M, Ledermann J, Lockley M, Macdonald N, McCormack M et al.
International Journal of Gynecological Cancer, Elsevier Bv, 101853-101853.  
01-04-2025

29P BRCA1 reversion mutations confer a fitness benefit to PARP inhibitor-resistant subclones in high grade serous ovarian cancer models
Khan MA, Hall A, Guscott M, Bakali N, McClelland S, Graham T, Lockley M
Esmo Open, Elsevier Bv vol. 10, 104187-104187.  
01-03-2025

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer
Mukherjee UA, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K, Dhanda H, Robinson K et al.
Bmj Open, Bmj vol. 14 (12), e091262-e091262.  
01-12-2024

Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004-2016) analysis.
Sullivan SM, Stoneham S, Lockley M, Frazier AL, Billmire DF, Poynter JN
Int J Gynecol Cancer vol. 34 (12), 1906-1913.  
01-12-2024

Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004–2016) analysis
Sullivan SM, Stoneham S, Lockley M, Frazier AL, Billmire DF, Poynter JN
International Journal of Gynecological Cancer, Elsevier Bv vol. 34 (12), 1906-1913.  
01-12-2024

Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer.
Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J et al.
International Journal of Gynecological Cancer : Official Journal of The International Gynecological Cancer Society vol. 34 (11), 1768-1774.  
01-11-2024

Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer
Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J et al.
International Journal of Gynecological Cancer, Elsevier Bv vol. 34 (11), 1768-1774.  
01-11-2024

Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
El-Shakankery KH, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, Tan W, Crusz SM et al.
Cancers, Mdpi Ag vol. 16 (21), 3590-3590.  
24-10-2024

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer
Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M et al.
Journal of The National Comprehensive Cancer Network, Harborside Press, Llc vol. 22 (2D) 
01-06-2024

Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T et al.
Eclinicalmedicine, Elsevier Bv vol. 69, 102453-102453.  
01-03-2024

Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M, Frazier AL
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 42 (6), 696-706.  
20-02-2024

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention
Nuttall Musson E, Miller RE, Mansour MR, Lockley M, Ledermann JA, Payne EM
Leukemia, Springer Science and Business Media Llc vol. 38 (1), 215-218.  
17-11-2023

Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and Myelodysplastic Syndrome: A Case Series
Nuttall Musson E, Lockley M, Mansour MR, Miller RE, Lederman J, Payne E
Blood, American Society of Hematology vol. 142 (Supplement 1), 5607-5607.  
02-11-2023

Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy
Wood GE, Bunting CP, Veli M, Arora R, Berney DM, Alifrangis C, MacDonald ND, Miller RE et al.
Frontiers in Oncology, Frontiers Media Sa vol. 13 
25-10-2023

Letter to Editor in Response to: Controlled Aspiration of Large Paediatric Ovarian Cystic Tumors
Graham R, Stoneham S, Lockley M, MacDonald ND
Journal of Pediatric Surgery, Elsevier Bv vol. 58 (10), 2061-2061.  
01-10-2023

Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE et al.
Bjog: An International Journal of Obstetrics &Amp; Gynaecology, Wiley vol. 131 (6), 848-857.  
26-09-2023

Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM et al.
Nature Communications, Springer Science and Business Media Llc vol. 14 (1) 
26-09-2023

Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer
Hockings H, Lakatos E, Huang W, Mossner M, Khan MA, Metcalf S, Nicolini F, Smith K et al.
In Cold Spring Harbor Laboratory 
25-07-2023

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM et al.
Nature Communications, Springer Science and Business Media Llc vol. 14 (1) 
20-07-2023

Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis
Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Burger Ramos M, Peerani E, Hirani P et al.
Nature Communications, Springer Nature vol. 14 (1) 
15-05-2023

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants inBRCA1andBRCA2
Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J et al.
Journal of Medical Genetics, Bmj vol. 60 (5), 440-449.  
01-11-2022

Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium
Fonseca A, Lobo J, Hazard FK, Gell J, Nicholls PK, Weiss RS, Klosterkemper L, Volchenboum SL et al.
British Journal of Cancer, Springer Science and Business Media Llc vol. 127 (9), 1577-1583.  
13-10-2022

2022-RA-1310-ESGO Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer
Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Morgan RD et al.
ESGO 2022 Congress. 
01-10-2022

A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer
Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H et al.
Gynecologic Oncology, Elsevier Bv vol. 167 (1), 96-106.  
01-10-2022

2022-RA-1443-ESGO Patient decision aids in genetic testing for women with ovarian cancer
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Miller R, Mills-Baldock T, Crusz S, Sun L et al.
ESGO 2022 Congress. 
01-10-2022

Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes -Múgica M, Elishaev E, Vang R et al.
European Journal of Cancer, Elsevier Bv vol. 173, 59-70.  
01-09-2022

600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials
Palmer KR, El-Shakankery KH, Kefas J, Gao K, Crusz S, Flynn M, Jonathan L, Lockley M et al.
Annals of Oncology, Elsevier Bv vol. 33, S820-S820.  
01-09-2022

Extracellular matrix educates a tumor macrophage phenotype found in ovarian cancer metastasis
Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Peerani E, Hirani P, Gauthier V et al.
In Cold Spring Harbor Laboratory 
14-08-2022

Abstract 53: The copy number landscape of early stage ovarian high grade serous carcinoma
Cheng Z, Mirza HB, Ennis DP, Smith P, Gavarró LM, Sokota C, Giannone G, Goranova T et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (12_Supplement), 53-53.  
15-06-2022

Abstract PR015: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer
Hockings H, Lockley M, Graham T, Lakatos E, Huang W
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (10_Supplement), PR015-PR015.  
15-05-2022

Abstract B001: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer
Hockings H, Lockley M, Graham T, Lakatos E, Huang W
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (10_Supplement), B001-B001.  
15-05-2022

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Cheng Z, Mirza H, Ennis DP, Smith P, Morrill Gavarró L, Sokota C, Giannone G, Goranova T et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 28 (13), 2911-2922.  
10-04-2022

Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study
Graham R, MacDonald ND, Lockley M, Miller R, Butler J, Murali K, Sarker S-J, Banerjee S et al.
European Journal of Obstetrics &Amp; Gynecology and Reproductive Biology, Elsevier Bv vol. 271, 138-144.  
01-04-2022

Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients
Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, Agarwal S, Sahdev A et al.
European Journal of Cancer, Elsevier Bv vol. 164, 105-113.  
01-03-2022

Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy
Hoare JI, Osmani B, O’Sullivan EA, Browne A, Campbell N, Metcalf S, Nicolini F, Saxena J et al.
Communications Biology, Springer Science and Business Media Llc vol. 5 (1) 
03-02-2022

The copy number landscape of early stage ovarian high grade serous carcinoma
Cheng Z, Mirza HB, Ennis DP, Smith P, Gavarro LM, Sokota C, Giannone G, Goranova T et al.
 
01-01-2022

423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers
Philpott S, Raikou M, Manchanda R, Evans G, Edmondson R, Menon U, Ahmed M, Woodward E et al.
Late Breaking Abstracts, Bmj Publishing Group Ltd, A373.2-A374.  
01-10-2021

414 Surgery for malignant ovarian germ cell tumours: a multicentre retrospective cohort study
Graham R, Macdonald N, Murali K, Sarker SJ, Miller R, Banerjee S, Butler J, Stoneham S et al.
ESGO 2021 Congress. 
01-10-2021

Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study
Oxley SG, Achampong YA, Sambandan N, Hughes DJ, Thomas M, Lockley M, Olaitan A
Acta Obstetricia Et Gynecologica Scandinavica, Wiley vol. 100 (11), 2091-2096.  
05-09-2021

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study
Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L et al.
Cancers, Mdpi Ag vol. 13 (17), 4344-4344.  
27-08-2021

LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham TA
Iscience, Elsevier Bv vol. 24 (8), 102889-102889.  
01-08-2021

Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’
Lockley M, Stoneham S, Shamash J, Pashankar F, Frazier L
European Journal of Cancer, Elsevier Bv vol. 152, 255-256.  
01-07-2021

The genomic landscape of early stage ovarian high grade serous carcinoma
Cheng Z, Mirza H, Ennis DP, Smith P, Gavarró LM, Sokota C, Giannone G, Goranova T et al.
In Cold Spring Harbor Laboratory 
05-05-2021

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA, Lockley M
Cell Death &Amp; Disease, Springer Science and Business Media Llc vol. 12 (4) 
14-04-2021

Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.
Gynecologic Oncology, Elsevier Bv vol. 161 (1), 328-329.  
01-04-2021

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J et al.
The Lancet Oncology, Elsevier Bv vol. 22 (2), 277-288.  
01-02-2021

Identification of a novel regulator of FANCD2 mediated DNA Repair
Tse WY, Maniati E, Wang J, Lockley M, Martin S
The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response 1 Feb 2021 - 14 Feb 2021. 
29-01-2021

LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham TA
 
06-01-2021

The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)
Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A et al.
British Journal of Cancer, Springer Science and Business Media Llc vol. 124 (2), 368-374.  
29-09-2020

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer
Hoare JI, Hockings H, Saxena J, Silva VL, Maniati E, Mirza HB, Huang W, Wood GE et al.
 
24-07-2020

Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Berney DM, Shamash J, Stoneham S, Lockley M
European Journal of Cancer, Elsevier Bv vol. 130, 267-268.  
01-05-2020

Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448]
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.
Gynecologic Oncology, Elsevier Bv vol. 157 (2), 558-559.  
01-05-2020

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process
McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L et al.
International Journal of Gynecological Cancer, Elsevier Bv vol. 30 (2), 221-226.  
01-02-2020

Role of Ki67 Proliferation Index and CD8 Tumour-Infitrating Lymphocyte Counts in Predicting Outcome in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) Showing No/Partial Response to Neoadjuvant Chemotherapy
Casey L, Powell A, Bohm S, Manchanda R, Lockley M, Kobel M, Singh N
 
01-01-2020

Ovarian germ cell tumour classification: views from the testis
Berney DM, Stoneham S, Arora R, Shamash J, Lockley M
Histopathology, Wiley vol. 76 (1), 25-36.  
17-12-2019

Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA
Macintyre G, Goranova TE, Silva DD, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 25 (22_Supplement), AP09-AP09.  
15-11-2019

EP870 Bevacizumab facilitates surgery in previously inoperable patients with low-grade serous ovarian cancer: a case series
Hockings H, Wood G, Lockley M
ESGO Annual Meeting Abstracts. 
01-11-2019

Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer
Hockings HA, Mossner M, Lakatos E, Graham T, Lockley M
 
01-11-2019

C-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer
Wood GE, Lockley M, Kermorgant S
 
01-11-2019

The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases
Heath O
 
24-10-2019

Surgical management of ovarian germ cell tumours
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Lockley M
European Urology Supplements, Elsevier Bv vol. 18 (4), 16-16.  
01-09-2019

The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)
Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A et al.
European Urology Supplements, Elsevier Bv vol. 18 (4), 33-33.  
01-09-2019

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.
Gynecologic Oncology, Elsevier Bv vol. 154 (2), 441-448.  
01-08-2019

Abstract 3801: Reversing chemoresistance in high grade serous ovarian cancer
Saxena J, Nicolini F, Lockley M
Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. 
01-07-2019

Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases
Heath OM, Maniati E, Belato C, Gopinathan G, Lecker L, Lakhani A, Pegrum C, McDermott J et al.
 
01-07-2019

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Ledermann J et al.
European Journal of Cancer, Elsevier Bv vol. 113, 19-27.  
01-05-2019

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al.
British Journal of Cancer, Springer Science and Business Media Llc vol. 120 (8), 868-868.  
13-03-2019

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results
Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R et al.
International Journal of Gynecological Cancer, Elsevier Bv vol. 29 (2), 353-356.  
01-02-2019

COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al.
 
01-01-2019

Ovarian cancer in adolescents and young adults
Lockley M, Stoneham SJ, Olson TA
Pediatric Blood &Amp; Cancer, Wiley vol. 66 (3) 
23-10-2018

Copy number signatures and mutational processes in ovarian carcinoma
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al.
Nature Genetics, Springer Science and Business Media Llc vol. 50 (9), 1262-1270.  
13-08-2018

Abstract A54: Generation and characterization of a novel panel of platinum-resistant HGSOC models
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M
 
01-08-2018

Abstract PR14: CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al.
 
01-08-2018

Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.
Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 36 (15_suppl), 5581-5581.  
20-05-2018

Mainstreamed genetic testing for women with ovarian cancer: first-year experience
Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L
Journal of Medical Genetics, Bmj vol. 56 (3), 195-198.  
13-03-2018

A multicentre analysis of malignant ovarian germ cell tumours: rationale for alignment of paediatric and adult practice and for chemotherapy de-escalation in specific subtypes
Lockley M, Newton C, Murali K, Ahmed A, Hockings H, Berney D, Shamash J, Banerjee S et al.
 
01-01-2018

Generation and characterization of a novel panel of platinum-resistant HGSOC models.
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M
 
01-01-2018

CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma.
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al.
 
01-01-2018

c-Met signalling and endocytosis in clear cell ovarian cancer
Wood GE, Heuss SF, Osagie I, Lockley M, Kermorgant S
 
01-01-2018

Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers.
Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al.
Cancer Discov 
01-12-2017

Copy-number signatures and mutational processes in ovarian carcinoma
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al.
In Cold Spring Harbor Laboratory 
09-08-2017

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo‐ovarian high‐grade serous carcinoma before and after neoadjuvant chemotherapy
Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ et al.
Histopathology, Wiley vol. 71 (5), 736-742.  
07-08-2017

Abstract AP24: CRISPR/CAS9–MEDIATED TRP53, BRCA1, BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA
Walton J, Blagih J, Farquharson M, Ennis D, Leung E, Dowson S, Tookman LA, Orange C et al.
 
31-05-2017

A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 35 (15_suppl), 2594-2594.  
20-05-2017

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al.
British Journal of Cancer, Springer Science and Business Media Llc vol. 116 (10), 1294-1301.  
30-03-2017

Immunohistochemical Expression of p53 and WT1 Is Retained Following Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC)
Ganesan R, Singh N, Casey L, Tam S, Farugi A, Prasad R, Boehm S, Lockley M et al.
 
01-01-2017

The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma
McDermott JR, Jones R, Lockley M, Balkwill FR
 
01-01-2017

Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer
La Russa M, Kokka F, Lockley M, Brockbank E
Journal of Obstetrics and Gynaecology, Informa Uk Limited, 1-3.  
06-12-2016

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 76 (20), 6118-6129.  
13-10-2016

A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH et al.
Clinical Cancer Research, American Association For Cancer Research 
27-06-2016

Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma
BALKWILL F, Anne Montfort, Oliver Pearce
Clinical Cancer Research, American Association For Cancer Research 
01-04-2016

Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer.
Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 22 (2_Supplement), B53-B53.  
15-01-2016

RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer
Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M et al.
Molecular Cancer Research, American Association For Cancer Research (Aacr) vol. 14 (1), 44-55.  
01-01-2016

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 33 (22), 2457-2463.  
01-08-2015

Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases
Montfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F
 
01-08-2015

Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity

Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (14), 2811-2821.  
14-07-2015

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL et al.
Molecular Oncology, Wiley vol. 9 (4), 791-805.  
29-12-2014

106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer
Browne AK, Tookman LA, Ingemarsdotter CK, Bouwman R, Pirlo K, Wang Y, Hodivala-Dilke KM, McNeish IA et al.
 
01-11-2014

Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.
Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T et al.
Faseb J vol. 27 (10), 4244-4253.  
01-10-2013

Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients
Boehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F
 
01-01-2013

[18F]Fluorodeoxyglucose PET and Volumetric CT analysis are early biomarkers of survival in platinum-sensitive relapsed ovarian cancer - a multicentre trial
Rockall AG, Avril NE, Lam R, Mozley PD, Iannone R, Lockley M, Parkinson C, McNeish IA et al.
 
01-01-2013

Failure of Translation of Human Adenovirus mRNA in Murine Cancer Cells Can be Partially Overcome by L4-100K Expression In Vitro and In Vivo
Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ et al.
Molecular Therapy, Elsevier Bv vol. 20 (9), 1676-1688.  
01-09-2012

The peritoneal tumour microenvironment of high‐grade serous ovarian cancer
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al.
The Journal of Pathology, Wiley vol. 227 (2), 136-145.  
18-04-2012

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials
Brais RJ, Davies SE, O’Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP et al.
Pancreatology, Elsevier Bv vol. 12 (1), 8-15.  
01-01-2012

M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer
Schultes BC, Lolkema MPJK, Chu CL, Zhou H, Long A, Lockley M, Avery W, Kurtagic E et al.
 
01-01-2012

Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells
Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al.
J Clin Invest vol. 121 (4), 1283-1297.  
01-04-2011

Inhibition of the Inflammatory Cytokine TNF-alpha Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression
Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA
Mol Ther vol. 19 (3), 490-499.  
01-03-2011

Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer
Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al.
Human Gene Therapy vol. 22 (10), A113-A113.  
01-01-2011

p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker
Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP et al.
Mol Cancer vol. 9 
03-07-2010

Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer
Salako MA, Connell CM, Shibata A, Graupner V, Lockley M, Balkwill FR, McNeish IA
 
15-04-2010

Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer
Lolkema M, Lockley M, Zhou H, Duffner J, Kishomoto TK, Tuveson DA
Cancer Research, American Association For Cancer Research (Aacr) vol. 70 (8_Supplement) 
15-04-2010

Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer
Lockley M, Eisen T
Therapy, Omics Publishing Group vol. 6 (1), 111-124.  
01-01-2009

Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA
Oncogene vol. 27 (22), 3081-3090.  
01-05-2008

Oncolytic adenoviral mutants define a novel mode of programmed cell death in ovarian cancer
Baird SK, Ingemarsdotter CK, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA
 
01-01-2008

Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging
Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA
Cancer Research, American Association For Cancer Research (Aacr) vol. 66 (18), 9178-9185.  
15-09-2006

Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: Comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin
Lockley M, Fernandez M, Wang YH, Li NF, Conroy S, Lemoine N, McNeish I
Cancer Res vol. 66 (2), 989-998.  
15-01-2006

E1A CR2 deletion mutant adenoviral vectors in ovarian cancer: combination with apoptosis inducers and monitoring with [18F] FLT-PET imaging
Baird SK, Lockley M, Leyton J, Aboagye EO, Lemoine NR, McNeish IA
 
01-01-2006

Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis
McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP, Lemoine NR
Exp Cell Res vol. 302 (1), 69-82.  
01-01-2005

Outcomes of critical illness in patients with haematological malignancy.
Oakervee HE, Gordon AC, Kaya B, Taussig DC, Lockley M, Barnett MJ, Rohatiner AZS, Lister TA et al.
 
01-01-2002

ecancermedicalscience

, Ecancer Global Foundation 

Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data
Cohen P, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.